Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
Provided By GlobeNewswire
Last update: Aug 18, 2025
August 18, 2025
Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial
in Familial Adenomatous Polyposis (FAP)
Read more at globenewswire.comNASDAQ:BDRX (8/29/2025, 8:07:57 PM)
5.54
+0.07 (+1.28%)
Find more stocks in the Stock Screener
